This study attempts to identify variables that can predict the development of progressive-or quiescent-type chronic GVHD (pq cGVHD) and transplant outcomes after the diagnosis of cGVHD in 99 patients who experienced acute GVHD (aGVHD) after allogeneic SCT. The prognostic significance of various clinical parameters at diagnosis of cGVHD was examined to determine the prognostic factors for GVHD-specific survival (GSS) in patients with pq cGVHD. Among 118 patients who experienced any degree of aGVHD, 99 were evaluated for cGVHD. The incidence of overall and extensive pq cGVHD at 2 years was estimated as 84.4 and 63.1%, respectively. A multivariate analysis showed that severe aGVHD (grade 3, 4) (P ¼ 0.022), primary treatment failure (P ¼ 0.009) and elevated alkaline phosphatase (P ¼ 0.001) were all significant independent factors predicting a higher overall incidence of pq cGVHD. The GSS and probability of systemic immunosuppressive treatment at 2 years after diagnosis of cGVHD were estimated as 55.9 and 51.9%. GVHD-specific survival was significantly associated with performance status (P ¼ 0.004) and lymphocytopenia (p1000/ll, P ¼ 0.022) at diagnosis of cGVHD by Cox's proportional hazard model. Severe aGVHD, primary treatment failure (PTF), lymphocytopenia and elevated alkaline phosphatase may be useful predictive factors for the development of pq cGVHD in patients who experience aGVHD after allogeneic SCT.
Introduction
Chronic graft-versus-host disease (cGVHD) is a systemic syndrome that has heterogeneous clinical manifestations and variable prognoses. 1 Clinically, cGVHD has been classified as progressive, quiescent or de novo according to its onset type. Whereas progressive-type cGVHD has a grim prognosis, quiescent, intermediate and de novo type have an excellent prognosis. 1, 2 Among the proposed risk factors for cGVHD, severity of acute GVHD (aGVHD) is regarded as the most powerful predictor of subsequent cGVHD. 1, 3 Thus, ascertaining the risk factors related to aGVHD or clinical factors manifested during aGVHD may aid in setting up management guidelines for progressive or quiescent cGVHD (pq cGVHD). It is accepted that aggressive initial treatment of severe aGVHD can prevent successive development of cGVHD from aGVHD. Previous investigations have always included de novo cGVHD in their analyses to identify the risk factors for cGVHD in a cohort of patients with or without aGVHD. 4, 5 Yet, it may be more reasonable to predict the risk of pq cGVHD in a patient group who experienced aGVHD, while predicting the risk of de novo cGVHD in a patient group without aGVHD. Clinically, it is important to focus specifically on pq cGVHD, rather than overall heterogeneous cGVHD, in order to set up an appropriate plan to minimize the risk of pq cGVHD progressing from aGVHD. However, data are still lacking on the risk factors for cGVHD following the occurrence of aGVHD.
Accordingly, building on a previous investigation 6 identifying poor prognostic factors (lymphocytopenia and visceral involvement) at the onset of aGVHD in patients with a history of aGVHD after allogeneic SCT, the present study attempted to identify variables that could predict the development of cGVHD, and patient outcomes after the diagnosis of cGVHD, in a cohort of 99 patients who experienced aGVHD after allogeneic SCT.
Patients and methods

Patient characteristics
In a previous study conducted by the current authors, 6 the patient cohort consisted of patients (n ¼ 141) who developed aGVHD requiring systemic immunosuppressive treatment, representing 141 (32.2%) out of 437 adult patients who underwent allogeneic SCT at the Asan Medical Center in Seoul and Kyungpook National University Hospital in Daegu, Korea, between January 1996 and January 2004. Using the same patient cohort for the present study, 23 cases with benign hematologic or nonhematologic diseases were excluded, leaving 118 patients for a retrospective study with the following diseases: acute myeloid leukemia (n ¼ 50), acute lymphoblastic leukemia (n ¼ 18), high-risk myelodysplastic syndrome (n ¼ 10), chronic myelogenous leukemia (n ¼ 32) and malignant lymphoma (n ¼ 8). Ninety-nine cases were available for clinical evaluation of cGVHD, excluding early mortality cases (n ¼ 18) and cases that did not reach the cGVHD screening on day 90 (n ¼ 1).
Various clinical and laboratory data were retrieved from the allogeneic SCT database and medical records at each hospital. Patient characteristics were as follows: median age was 34.0 years (range 15-57 years), and male to female ratio was 61:39 (n ¼ 60:39). Thirty-three patients (33%) had advanced disease at the time of transplantation. HLA matching for donor selection was based on serologic typing for the HLA-A, -B and -C antigens and molecular typing for the HLA-DRB1 antigen. HLA-identical sibling transplants were performed in 68 cases (69%), HLA-identical unrelated transplants in 28 cases (28%) and partially mismatched transplants in three cases (3%) ( Table 1) .
Transplantation procedures
Transplantation procedures were conducted as previously described. 7, 8 Briefly, the conditioning regimens were myeloablative busulfan/cytoxan (BuCy; n ¼ 82) or fludarabinebased reduced-intensity conditioning (n ¼ 17). Sixty patients received unmanipulated marrow, whereas 39 patients received granulocyte colony-stimulating factor-mobilized peripheral blood stem cells. Prophylaxis against aGVHD consisted of cyclosporin A and methotrexate in 81 patients, whereas 18 patients received cyclosporin A alone. Infection prophylaxis consisted of ciprofloxacin (250 mg b.i.d., p.o.)/ metronidazole (500 mg t.i.d., p.o.)/fluconazole (100 mg q.d., p.o.), at initiation of conditioning, and acyclovir (600 mg b.i.d., p.o.) from day À1 until day þ 180. Co-trimoxazole was started after engraftment. All patients received irradiated blood products that had been depleted of leukocytes using filters.
The treatment regimen for aGVHD was as previously described. 6 The frontline regimen for the treatment of cGVHD was heterogeneous according to the number of agents used: a regimen using a single agent was given to 12 patients (15%), two agents were given to 45 patients (58%) and three agents in 21 patients (27%). Among the 78 patients, 36 (46%) experienced primary treatment failure. The commonly adopted second-line agent in these 36 patients was mycophenolate mofetil in 25 patients (69%), followed by FK506 in 20 patients (56%), prednisone in 16 patients (44%), cyclosporin A in four patients (11%), thalidomide in three patients (8%) and antithymocyte globulin/antilymphocyte globulin in three patients (8%), with 15 cases (42%) treated with a single-agent regimen and 15 (42%) and six cases (16%) treated with a combination regimen of two agents or three agents, respectively.
Assessment of potential risk factors
The following clinical parameters were assessed: patient age, sex, disease status at transplantation, donor type, stem cell source, donor-recipient sex pair, HLA disparity, GVHD prophylaxis and organs involved at the onset (skin, liver and lower gastrointestinal tract (GIT)). The following laboratory parameters were also obtained; serum concentrations of alanine aminotransferase, alkaline phosphatase, total bilirubin and albumin, peripheral blood absolute lymphocyte count (obtained by multiplying the white blood cell count by the lymphocyte fraction, as determined by manual counting) and peripheral blood platelet counts.
Definitions
The diagnosis of aGVHD was made as previously described by consensus criteria. 6, 9 Liver involvement was determined to be present when the serum bilirubin level was elevated to 2.0 mg/dl or higher and this could not be explained by other causes, such as veno-occlusive disease of the liver, drugs, sepsis, hepatitis, hemolysis or biliary tract obstruction. Lower GIT involvement was determined to be present when the patient experienced diarrhea of over 500 ml/day and stool or colonoscopic examination showed inflammatory changes with no documented pathogens. Upper GIT involvement was determined to be present when the patient experienced persistent nausea and gastroscopic examination showed mucosal changes consistent with GVHD without evidence of viral infection. The day of onset of aGVHD was defined as the date of initiation of clinical symptom(s) or sign(s) of aGVHD. Primary treatment failure was defined as the necessity for secondary treatment for aGVHD due to a lack of response or progression following initial treatment, or patient death due to aGVHD while receiving initial treatment. 6 In addition, the diagnosis of cGVHD was made according to the revised Seattle criteria. 10 The day of onset for overall and extensive cGVHD was defined as the date of initiation of clinical sign(s) of cGVHD or the date of histological confirmation.
Advanced disease status was defined as acute leukemia beyond the first remission, chronic myeloid leukemia beyond the first chronic phase and multiple relapsing or chemo-resistant malignancies.
Statistics
Results were analyzed according to information available on April 2005. The day of the stem cell infusion was defined as day 0.
The primary end point of the present study was the incidence of overall and extensive pq cGVHD after the occurrence of aGVHD, defined as the interval from day 0 to the date of confirmed cGVHD. The second end point was the GVHD-specific survival (GSS) of the cohort, defined as the interval from onset of cGVHD to death owing to GVHD-related complications without relapse of the underlying malignancy. Patients who relapsed due to their underlying malignancy were censored at the time of relapse. Overall survival (OS) was defined as the time from transplantation until death from any cause, whereas nonrelapse mortality (NRM) was defined as a death unrelated to recurrence or disease progression, such as an exacerbation of GVHD, opportunistic infection with or without GVHD, respiratory failure, bleeding, graft failure, hepatitis, veno-occlusive disease or thrombotic thrombocytopenic purpura. The cumulative incidence of relapse was defined as the time from transplantation to disease progression.
The potential risk factors for the overall development of cGVHD or development of extensive cGVHD were analyzed using a log-rank test. Curves for GSS and OS were plotted according to the Kaplan-Meier method and compared using a log-rank test. For multivariate survival analyses using Cox's proportional hazard model to define the risk factors for the development of overall or extensive cGVHD, or prognostic factors for GSS, variables with a P-value o0.1, as determined by a univariate analysis, were considered for entry into the model selection procedure based on Cox's proportional hazard model with backward conditional procedures. The following clinical parameters were included in the final model for subsequent cGVHD development: aGVHD (grade 0-2 vs 3, 4), primary treatment failure for aGVHD, visceral involvement, hepatic involvement, lower GIT involvement, alkaline phosphatase (o vs X160 IU/l), platelet count (o vs X50 000/ml) and absolute lymphocyte count (100/ml). Furthermore, in terms of GSS, the performance status (ECOG 0, 1 vs 2-4), diarrhea, progressive-type onset, extensive skin involvement, thrombocytopenia (o vs X100 000/ml), lymphocytopenia at the diagnosis of cGVHD (o vs X1000/ml) and elevated bilirubin (o vs X2 mg/dl) were included in the final model. The hazard ratio and 95% confidence interval were also estimated with a predetermined risk of 1.0. A predictive model for pq cGVHD was generated based on the risk factors identified from Cox's hazard regression model. For the overall prediction of pq cGVHD, grade of aGVHD (grade 1-2 vs 3-4), primary treatment failure for aGVHD and elevated alkaline phosphatase (o vs X160 IU/l) were used, whereas for extensive pq cGVHD, the grade of aGVHD (grade 1-2 vs 3-4), primary treatment failure for aGVHD and lymphocytopenia at the diagnosis of aGVHD (o vs X100/ml) were incorporated into the model. The predictive score was calculated by summing the risk factors for pq cGVHD. The cumulative incidence of pq cGVHD according to the predictive score was analyzed using a log-rank test and plotted using the Kaplan-Meier method. A cutoff P-value of 0.05 was adopted for all statistical analyses. Statistical data were obtained using an SPSS software package (SPSS 11.5 Inc., Chicago, IL, USA).
Results
Transplant outcomes
Transplant outcomes are summarized in Table 1 . With a median follow-up duration for the surviving patients of 857 days (range 434-2306 days), 44 patients died, resulting in a 2-year OS rate of 48.574.8% (Figure 1a) . Thirty-six patients died owing to non-relapse mortalities without relapse of the underlying malignancy (2-year NRM rate, 46.774.8%; Figure 1b) , whereas eight patients died of progression of their primary disease, where the cumulative incidence of relapse at 2 years was 20.474.5% (Figure 1b) . Overall, the GSS rate and probability of systemic immunosuppression at 2 years after the diagnosis of cGVHD were 55.975.8 and 51.976.2%, respectively (Figure 1c ).
Risk factors for development of chronic GVHD
Clinical characteristics of the patients at the onset of aGVHD are summarized in Table 2 . Briefly, among the total of 118 patients, 99 (84%) and 58 patients (49%) exhibited grade 2-4 and grade 3, 4 aGVHD, respectively. Meanwhile, 101 patients (86%) had skin involvement, 57 (48%) had liver involvement and 70 (59%) had lower GIT involvement. Among the 99 patients evaluated for cGVHD out of the total 118 patients who experienced aGVHD, 78 patients (79%) were diagnosed with cGVHD at a median of 106 days after transplantation (range 92-688 days) and 80 days after the diagnosis of aGVHD (range 39-657 days), whereas extensive cGVHD was diagnosed in 59 patients (60%) with a median of 101 days after transplantation (range 92-458 days) and 91 days after the diagnosis of aGVHD (range 39-427 days; Table 2 ). The 2-year cumulative incidence for the overall and extensive pq cGVHD was 84.473.6 and 63.174.6%, respectively, as shown in Figure 2 .
Univariate analysis showed that the statistically significant risk factors for the overall development of pq cGVHD included aGVHD, grade 3, 4 (Po0.001; Figure 3a) , primary treatment failure (Po0.001; Figure 3b ), elevated alkaline phosphatase (P ¼ 0.003; Figure 3c ), hepatic involvement (P ¼ 0.004), visceral involvement (P ¼ 0.016) and lower GIT involvement (P ¼ 0.035). Meanwhile, for extensive cGVHD, the significant risk factors identified by univariate analysis were aGVHD grade 3, 4 (Po0.001; Figure 3d ), primary treatment failure (Po0.001; Figure 3e ), lymphocytopenia (Po0.001; Figure 3f ) and hepatic involvement (P ¼ 0.010).
Among the patients who developed cGVHD, only seven (17%) out of 42 patients without primary treatment failure showed progressive-type cGVHD, whereas 22 (61%) out of 36 patients with primary treatment failure showed progressive-type cGVHD (Po0.001). Furthermore, among the 58 patients without primary treatment failure, 16 patients (28%) did not develop cGVHD, 16 patients (28%) developed limited cGVHD and 26 patients (45%) developed extensive cGVHD, whereas among the 41 patients with primary treatment failure, five patients (12%) did not develop cGVHD, three patients (7%) developed limited cGVHD and the remaining 33 patients (80%) experienced extensive cGVHD.
Moreover, the multivariate analysis showed that severe aGVHD (grade 3, 4) (P ¼ 0.022), primary treatment failure (P ¼ 0.009) and elevated alkaline phosphatase (P ¼ 0.001) were significant independent factors predicting a higher overall incidence of pq cGVHD, whereas severe aGVHD (Po0.001), primary treatment failure (P ¼ 0.010) and lymphocytopenia (P ¼ 0.031) predicted a higher incidence of extensive pq cGVHD (Table 3) .
When generating predictive models for the development of cGVHD based on the risk factors identified above, patients could be stratified according to their risk of developing pq cGVHD (Figure 4 ). The group with a predictive score of 0 (low risk) showed a 48.6710.1% 1-year overall incidence of cGVHD, whereas the group with a predictive score of 1-3 (high risk) showed a 91.973.4% incidence (Po0.001; Figure 4a ). In contrast, the group with Prediction of progressive-or quiescent-type chronic GVHD SK Sohn et al a predictive score of 0 (low risk) showed a 34.277.5% 1-year incidence of extensive pq cGVHD, whereas the group with a predictive score of 1 (intermediate risk) showed a 59.6710.6% incidence and the group with a predictive score of 2-3 (high risk) showed a 92.275.2% incidence (Po0.001; Figure 4b ).
Prognostic factors for survival after the diagnosis of cGVHD following occurrence of aGVHD Clinical characteristics of the patients at diagnosis of cGVHD are summarized in Table 2 . Prognostic factors after diagnosis of cGVHD were evaluated by GSS. Among the clinical parameters obtained at the diagnosis of cGVHD, performance status (ECOG X2, Po0.001; Figure 5a ), elevated bilirubin (X2 mg/dl, Po0.001), a progressive-type onset (P ¼ 0.002; Figure 5b ), diarrhea (P ¼ 0.003), lymphocytopenia (p1000/ml, P ¼ 0.005; Figure 5c ), thrombocytopenia (p100 000/ml, P ¼ 0.01, Figure 5d ) and weight loss (P ¼ 0.01) were all found to be significantly associated with a shorter GSS, whereas extensive skin involvement, elevated alanine transaminase or alkaline phosphatase and involvement of the liver, oral cavity, eyes, lungs or musculoskeletal system were not found to influence GSS. The new prognostic scales for cGVHD proposed by Akpek et al. 5, 11 and Lee et al. 12 were also evaluated in the present cohort (n ¼ 78). According to the prognostic system of Akpek et al.,
5 the group with grade 1 showed a 73.9710.3% 2-year GSS rate, the group with grade 2 showed a 55.579.2% rate and the group with grade 3 showed a 47.6710.9% rate (P ¼ 0.05; Figure 5e ). Meanwhile, according to the severity score proposed by Lee et al.,
12 the low-risk group showed a 80.177.5% 2-year GSS rate, the intermediate-risk group showed a 44.9710.1% rate and the high-risk group showed a 29.6712.3% rate (Po0.001; Figure 5f ).
Multivariate analysis showed that a poor performance status (ECOG X2, Po0.001) and lymphocytopenia (p1000/ml, P ¼ 0.045) were significant independent factors predicting a decreased GSS after the diagnosis of cGVHD (Table 4) .
Discussion
The appropriate management of cGVHD is one of the most important considerations for successful allogeneic SCT. 10 For patients experiencing aGVHD, more vigilant measures towards aGVHD are particularly needed to reduce the chance of developing pq cGVHD. As such, it is important to identify which factors related to aGVHD or situations during the occurrence of aGVHD should be monitored or corrected to minimize morbidity due to the subsequent development of cGVHD. Although the current study was designed on the basis of a previous study, 6 which reported risk factors identified from a circumscribed patient group who experienced aGVHD after allogeneic SCT, the rationale of excluding de novo cGVHD in the present study can be supported based on the following issues: (1) No clinical factor related to aGVHD can be associated with Table 3 Risk factor analysis for development of progressive-or quiescent-type chronic GVHD For the analysis, the following clinical parameters were included in the final models for subsequent chronic GVHD development: acute GVHD (grade 0-2 vs 3, 4), primary treatment failure for acute GVHD, visceral involvement, hepatic involvement, lower gastrointestinal tract involvement, alkaline phosphatase (o vs X160 IU/l), platelet count (o vs X50 000/ml) and absolute lymphocyte count (100/ml). patients suffering from de novo cGVHD. Thus, it is more reasonable to predict the risk of pq cGVHD in a separate cohort of patients who experienced aGVHD. Notwithstanding, identifying the predictive factors for de novo cGVHD is also needed in a patient group without a history of aGVHD. (2) The proposed pathogenesis of de novo cGVHD, considered to be deregulated humoral immunity, [13] [14] [15] is different from that of pq cGVHD, where alloreactive T cells are the central mechanism. Accordingly, in terms of prognosis, as a relatively homogeneous subgroup with intermediate and unfavorable prognoses was included in the current study, the results need to be interpreted differently from the previous study that included all types of cGVHD. The prediction of cGVHD based on the clinical situation of aGVHD could possibly improve transplant outcomes by providing the chance to prepare for subsequent pq cGVHD. Clinically, the stratification of patients with a history of aGVHD using the predictive model generated from the three risk factors identified in the present study may aid in the development of appropriate guidelines for the prevention or early management of pq cGVHD. For example, the tapering schedule of immunosuppressive drugs can be adopted differently according to the patient's predictive score.
In the current study, grade 3, 4 aGVHD, primary treatment failure, elevated alkaline phosphatase and lymphocytopenia at diagnosis of aGVHD were all identified as risk factors for developing pq cGVHD. However, HLA disparity or GVHD prophylaxis regimen was not found to have any influence on the subsequent development of cGVHD. Stem cell source was also unrelated to the development of cGVHD in the patient group that had experienced aGVHD.
Nonetheless, the present study found that severe aGVHD was an independent risk factor for pq cGVHD, which is consistent with the results of a previous investigation. 16 In addition, the contribution of primary treatment failure to the development of subsequent cGVHD was also found to be substantial, implying that patients with severe aGVHD may benefit from more aggressive treatment without delay.
Furthermore, lymphocytopenia at diagnosis of cGVHD was identified as a risk factor for extensive pq cGVHD. Similarly, in a previous investigation that identified lymphocytopenia at diagnosis of aGVHD as a prognostic factor for aGVHD, 6 it was proposed that this was mediated through the action of proinflammatory cytokines, such as interferon-g and tumor necrosis factor-a, which impair lymphocyte expansion upon mitogenic stimulation 17, 18 and cause bone marrow dysfunction. 18, 19 cGVHD can also occur in the environment of a cytokine storm. Accordingly, lymphocytopenia at diagnosis of cGVHD can be a predictor for cGVHD, whereas lymphocytopenia at diagnosis of aGVHD can be an indicator of the severity of aGVHD.
The contribution of elevated alkaline phosphatase at the time of aGVHD on the subsequent development of pq cGVHD can be explained as follows: elevated alkaline phosphatase reflects cholestatic activity, rather than the hepatitis-like activity of GVHD, which means that the main target of cGVHD is not the hepatocytes, but rather the bile duct. The similarity of hepatic GVHD to primary biliary cirrhosis also supports this finding. 20 In addition, recent advances in understanding the effect of chemokines on GVHD have found that alloreactive T cells expressing CCR5 and its ligand CCL3 play a pivotal role in liver GVHD. 21, 22 Thus, these alloreactive T cells recruiting in the liver during the initial stage of aGVHD may subsequently promote hepatic GVHD at the later stage of cGVHD.
The prognostic value of various clinical parameters at the onset of cGVHD was also evaluated using the GSS to enable a more precise evaluation of the prognosis of cGVHD than OS. The GSS of the current cohort was estimated as 55.9%, which seemed to be relatively lower than that in another study. 4 However, the explanation for this was the poor prognostic characteristics of the present cohort with regard to cGVHD.
In conclusion, the current study suggests that severe aGVHD, primary treatment failure of aGVHD, lymphocytopenia and elevated alkaline phosphatase can be utilized as predictive factors in relation to the risk of pq cGVHD. Thus, further studies involving a larger number of patients and different populations of patients are warranted. Table 4 Prognostic factor analysis for GVHD-specific survival after diagnosis of chronic GVHD using Cox's multivariate survival analysis For the analysis, the following clinical parameters were included in the final models for GVHD-specific survival: performance status (ECOG 0, 1 vs 2-4), weight loss, diarrhea, progressive-type onset, extensive skin involvement, thrombocytopenia (o vs X100 000/ml), lymphocytopenia at diagnosis of chronic GVHD (o vs X1000/ml) and elevated bilirubin (o vs X2 mg/dl).
